Differential impact of diverse anticancer chemotherapeutics on the Cdc25A-degradation checkpoint pathway
- 15 January 2005
- journal article
- research article
- Published by Elsevier in Experimental Cell Research
- Vol. 302 (2), 162-169
- https://doi.org/10.1016/j.yexcr.2004.08.035
Abstract
No abstract availableKeywords
This publication has 35 references indexed in Scilit:
- Cdc25A phosphatase: combinatorial phosphorylation, ubiquitylation and proteolysisOncogene, 2004
- Targeting the checkpoint kinases: chemosensitization versus chemoprotectionNature Reviews Cancer, 2004
- Chk1 and Chk2 kinases in checkpoint control and cancerCancer Cell, 2003
- ATM and related protein kinases: safeguarding genome integrityNature Reviews Cancer, 2003
- Mammalian G1- and S-phase checkpoints in response to DNA damageCurrent Opinion in Cell Biology, 2001
- Cell cycle checkpoint signaling through the ATM and ATR kinasesGenes & Development, 2001
- The ATM–Chk2–Cdc25A checkpoint pathway guards against radioresistant DNA synthesisNature, 2001
- The DNA damage response: putting checkpoints in perspectiveNature, 2000
- Human Cdc25 A inactivation in response to S phase inhibition and its role in preventing premature mitosisEMBO Reports, 2000
- Rapid Destruction of Human Cdc25A in Response to DNA DamageScience, 2000